Eris Lifesciences Ltd (ERIS) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Manufacturing shift to the new Bhopal facility will add 150-200 basis points to gross margin by Q2 next year, along with significant tax benefits.
- Management confirmed the major capex cycle ends in FY27, with capital allocation priority shifting to reducing net debt of INR 2,144 crores.
- The company plans to launch three insulin analogs in FY28, targeting a INR 2,500 crore market, and has received approval for recombinant Semaglutide clinical trials.
Performance Overview
- Delivered consolidated year-on-year revenue growth of 10.6% in the second quarter.
- Domestic Branded Formulation (DBF) business reported strong growth of 14.1% in Q2, or 16.5% adjusted for the Zorvia business.
- Profit After Tax saw a significant year-on-year increase of 39.2% for the quarter.
- Maintained leadership in the GLP-1 segment by units and prescriptions, with the market expected to double in the next year.
- Achieved a key milestone with the approval to commence clinical trials for recombinant Semaglutide, strengthening the biologics pipeline.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.